20-254 Search Results


  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 91
    ATCC rhodotorula sp
    Antimicrobial activities of native EeCentrocin 1, EeStrongylocin 2 and synthesised analogues of EeCentrocin 1 and 2. LC = light chain, HC = heavy chain, HC-diBr = peptide with two brominated Trp residues.
    Rhodotorula Sp, supplied by ATCC, used in various techniques. Bioz Stars score: 91/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/rhodotorula sp/product/ATCC
    Average 91 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    rhodotorula sp - by Bioz Stars, 2024-02
    91/100 stars
      Buy from Supplier

    93
    Proteintech igf 1r specific antibody
    ( A ) <t>IGF-1R,</t> CDC42, p85α, p-ERK and ERK mRNA levels were determined by qPCR in ER-positive cells transfected with a miR-29a mimic or miR-29a inhibitor. ( B , C ) Western blotting analysis was performed to monitor IGF-1R, CDC42, p85α, p-ERK and ERK expression in ER-positive cells transfected with a miR-29a mimic or miR-29a inhibitor. The results showed that ERK, CDC42 and p85α are the target genes of miR-29a; however, miR-29a promotes breast cancer cell growth and proliferation mainly by activating ERK phosphorylation. * p < 0.05.
    Igf 1r Specific Antibody, supplied by Proteintech, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/igf 1r specific antibody/product/Proteintech
    Average 93 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    igf 1r specific antibody - by Bioz Stars, 2024-02
    93/100 stars
      Buy from Supplier

    93
    Novus Biologicals sam68
    ( A ) <t>IGF-1R,</t> CDC42, p85α, p-ERK and ERK mRNA levels were determined by qPCR in ER-positive cells transfected with a miR-29a mimic or miR-29a inhibitor. ( B , C ) Western blotting analysis was performed to monitor IGF-1R, CDC42, p85α, p-ERK and ERK expression in ER-positive cells transfected with a miR-29a mimic or miR-29a inhibitor. The results showed that ERK, CDC42 and p85α are the target genes of miR-29a; however, miR-29a promotes breast cancer cell growth and proliferation mainly by activating ERK phosphorylation. * p < 0.05.
    Sam68, supplied by Novus Biologicals, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/sam68/product/Novus Biologicals
    Average 93 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    sam68 - by Bioz Stars, 2024-02
    93/100 stars
      Buy from Supplier

    93
    Proteintech igf1r
    ( A ) <t>IGF-1R,</t> CDC42, p85α, p-ERK and ERK mRNA levels were determined by qPCR in ER-positive cells transfected with a miR-29a mimic or miR-29a inhibitor. ( B , C ) Western blotting analysis was performed to monitor IGF-1R, CDC42, p85α, p-ERK and ERK expression in ER-positive cells transfected with a miR-29a mimic or miR-29a inhibitor. The results showed that ERK, CDC42 and p85α are the target genes of miR-29a; however, miR-29a promotes breast cancer cell growth and proliferation mainly by activating ERK phosphorylation. * p < 0.05.
    Igf1r, supplied by Proteintech, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/igf1r/product/Proteintech
    Average 93 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    igf1r - by Bioz Stars, 2024-02
    93/100 stars
      Buy from Supplier

    93
    Proteintech anti igf1r
    circVAPA promotes the progression of SCLC through the miR-377-3p and miR-494-3p <t>/IGF1R/AKT</t> axis. a and b Western blot analysis of the effects of circVAPA or miR-377-3p / miR-494-3p on IGF1R, AKT, and its downstream protein expression in SCLC cells. 377 inhi, miR-377 inhibitor, 494 inhi, miR-494 inhibitor; 377 mimic, miR-377 mimic; 494 mimic, miR-494 mimic. c Western blot analysis of the effect of overexpressing circVAPA or silencing IGF1R on AKT and its downstream protein expression in SCLC cells. d Western blot analysis of the effect of overexpressing circVAPA or IGF1R inhibitor (drug BMS-536924) on AKT and its downstream protein expression in SCLC cells. e The relative luciferase activities were detected in 293T cells after co-transfection with Lu- IGF1R -WT and mimic-NC or the circVAPA overexpression plasmid or miR-377-3p / miR-494-3p mimics, respectively. The firefly luciferase activities were measured and normalized to renilla luciferase activities (F/R). f-g Representative images of immunohistochemistry analysis of IGF1R ( f ) and p-AKT ( g ) in three independent SCLC cases. Scale bar, 50 μm. SCR, siRNA with scrambled sequences; si- circVAPA , the co-transfection of two independent siRNAs target circVAPA ; EV, the empty vector; circVAPA , the circVAPA overexpression plasmid; miR-377 mimic/ miR-494 mimic, transiently overexpressing miR-377-3p / miR-494-3p , respectively; miR-377 inhibitor/ miR-494 inhibitor, transiently suppressing miR-377-3p / miR-494-3p , respectively; si- IGF1R , an independent siRNA targeting IGF1R ; IGF1Ri, the addition of IGF1R inhibitor (drug BMS-536924). (All data are presented as the mean ± SD; ns, no significance; * P < 0.05; ** P < 0.01; *** P < 0.001 by two-tailed Student’s t-test). Three independent assays were performed in the above assays. *** miR-377 / miR-494 in this article represents miR-377-3p / miR-494-3p , respectively
    Anti Igf1r, supplied by Proteintech, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/anti igf1r/product/Proteintech
    Average 93 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    anti igf1r - by Bioz Stars, 2024-02
    93/100 stars
      Buy from Supplier

    Image Search Results


    Antimicrobial activities of native EeCentrocin 1, EeStrongylocin 2 and synthesised analogues of EeCentrocin 1 and 2. LC = light chain, HC = heavy chain, HC-diBr = peptide with two brominated Trp residues.

    Journal: PLoS ONE

    Article Title: Novel Antimicrobial Peptides EeCentrocins 1, 2 and EeStrongylocin 2 from the Edible Sea Urchin Echinus esculentus Have 6-Br-Trp Post-Translational Modifications

    doi: 10.1371/journal.pone.0151820

    Figure Lengend Snippet: Antimicrobial activities of native EeCentrocin 1, EeStrongylocin 2 and synthesised analogues of EeCentrocin 1 and 2. LC = light chain, HC = heavy chain, HC-diBr = peptide with two brominated Trp residues.

    Article Snippet: The synthetic peptides (see section ) were also screened for antifungal activity against Candida albicans (ATCC 10231), Saccharomyces cerevisiae , Rhodotorula sp., Aureobasidium pullulans and Cladosporium sp .

    Techniques: Concentration Assay

    ( A ) IGF-1R, CDC42, p85α, p-ERK and ERK mRNA levels were determined by qPCR in ER-positive cells transfected with a miR-29a mimic or miR-29a inhibitor. ( B , C ) Western blotting analysis was performed to monitor IGF-1R, CDC42, p85α, p-ERK and ERK expression in ER-positive cells transfected with a miR-29a mimic or miR-29a inhibitor. The results showed that ERK, CDC42 and p85α are the target genes of miR-29a; however, miR-29a promotes breast cancer cell growth and proliferation mainly by activating ERK phosphorylation. * p < 0.05.

    Journal: Oncotarget

    Article Title: miR-29a regulated ER-positive breast cancer cell growth and invasion and is involved in the insulin signaling pathway

    doi: 10.18632/oncotarget.15928

    Figure Lengend Snippet: ( A ) IGF-1R, CDC42, p85α, p-ERK and ERK mRNA levels were determined by qPCR in ER-positive cells transfected with a miR-29a mimic or miR-29a inhibitor. ( B , C ) Western blotting analysis was performed to monitor IGF-1R, CDC42, p85α, p-ERK and ERK expression in ER-positive cells transfected with a miR-29a mimic or miR-29a inhibitor. The results showed that ERK, CDC42 and p85α are the target genes of miR-29a; however, miR-29a promotes breast cancer cell growth and proliferation mainly by activating ERK phosphorylation. * p < 0.05.

    Article Snippet: The following antibodies were purchased from ProteinTech group, Inc., USA: a GAPDH antibody (60004-1), a CDK6 antibody (14052-1), and an IGF-1R-specific antibody (20254-1).

    Techniques: Transfection, Western Blot, Expressing

    The results show that miR-29a expression was down-regulated by IGF-1R-siRNA but not p85α-siRNA or Cdc42-siRNA. * p < 0.05.

    Journal: Oncotarget

    Article Title: miR-29a regulated ER-positive breast cancer cell growth and invasion and is involved in the insulin signaling pathway

    doi: 10.18632/oncotarget.15928

    Figure Lengend Snippet: The results show that miR-29a expression was down-regulated by IGF-1R-siRNA but not p85α-siRNA or Cdc42-siRNA. * p < 0.05.

    Article Snippet: The following antibodies were purchased from ProteinTech group, Inc., USA: a GAPDH antibody (60004-1), a CDK6 antibody (14052-1), and an IGF-1R-specific antibody (20254-1).

    Techniques: Expressing

    circVAPA promotes the progression of SCLC through the miR-377-3p and miR-494-3p /IGF1R/AKT axis. a and b Western blot analysis of the effects of circVAPA or miR-377-3p / miR-494-3p on IGF1R, AKT, and its downstream protein expression in SCLC cells. 377 inhi, miR-377 inhibitor, 494 inhi, miR-494 inhibitor; 377 mimic, miR-377 mimic; 494 mimic, miR-494 mimic. c Western blot analysis of the effect of overexpressing circVAPA or silencing IGF1R on AKT and its downstream protein expression in SCLC cells. d Western blot analysis of the effect of overexpressing circVAPA or IGF1R inhibitor (drug BMS-536924) on AKT and its downstream protein expression in SCLC cells. e The relative luciferase activities were detected in 293T cells after co-transfection with Lu- IGF1R -WT and mimic-NC or the circVAPA overexpression plasmid or miR-377-3p / miR-494-3p mimics, respectively. The firefly luciferase activities were measured and normalized to renilla luciferase activities (F/R). f-g Representative images of immunohistochemistry analysis of IGF1R ( f ) and p-AKT ( g ) in three independent SCLC cases. Scale bar, 50 μm. SCR, siRNA with scrambled sequences; si- circVAPA , the co-transfection of two independent siRNAs target circVAPA ; EV, the empty vector; circVAPA , the circVAPA overexpression plasmid; miR-377 mimic/ miR-494 mimic, transiently overexpressing miR-377-3p / miR-494-3p , respectively; miR-377 inhibitor/ miR-494 inhibitor, transiently suppressing miR-377-3p / miR-494-3p , respectively; si- IGF1R , an independent siRNA targeting IGF1R ; IGF1Ri, the addition of IGF1R inhibitor (drug BMS-536924). (All data are presented as the mean ± SD; ns, no significance; * P < 0.05; ** P < 0.01; *** P < 0.001 by two-tailed Student’s t-test). Three independent assays were performed in the above assays. *** miR-377 / miR-494 in this article represents miR-377-3p / miR-494-3p , respectively

    Journal: Molecular Cancer

    Article Title: CircVAPA promotes small cell lung cancer progression by modulating the miR-377-3p and miR-494-3p /IGF1R/AKT axis

    doi: 10.1186/s12943-022-01595-9

    Figure Lengend Snippet: circVAPA promotes the progression of SCLC through the miR-377-3p and miR-494-3p /IGF1R/AKT axis. a and b Western blot analysis of the effects of circVAPA or miR-377-3p / miR-494-3p on IGF1R, AKT, and its downstream protein expression in SCLC cells. 377 inhi, miR-377 inhibitor, 494 inhi, miR-494 inhibitor; 377 mimic, miR-377 mimic; 494 mimic, miR-494 mimic. c Western blot analysis of the effect of overexpressing circVAPA or silencing IGF1R on AKT and its downstream protein expression in SCLC cells. d Western blot analysis of the effect of overexpressing circVAPA or IGF1R inhibitor (drug BMS-536924) on AKT and its downstream protein expression in SCLC cells. e The relative luciferase activities were detected in 293T cells after co-transfection with Lu- IGF1R -WT and mimic-NC or the circVAPA overexpression plasmid or miR-377-3p / miR-494-3p mimics, respectively. The firefly luciferase activities were measured and normalized to renilla luciferase activities (F/R). f-g Representative images of immunohistochemistry analysis of IGF1R ( f ) and p-AKT ( g ) in three independent SCLC cases. Scale bar, 50 μm. SCR, siRNA with scrambled sequences; si- circVAPA , the co-transfection of two independent siRNAs target circVAPA ; EV, the empty vector; circVAPA , the circVAPA overexpression plasmid; miR-377 mimic/ miR-494 mimic, transiently overexpressing miR-377-3p / miR-494-3p , respectively; miR-377 inhibitor/ miR-494 inhibitor, transiently suppressing miR-377-3p / miR-494-3p , respectively; si- IGF1R , an independent siRNA targeting IGF1R ; IGF1Ri, the addition of IGF1R inhibitor (drug BMS-536924). (All data are presented as the mean ± SD; ns, no significance; * P < 0.05; ** P < 0.01; *** P < 0.001 by two-tailed Student’s t-test). Three independent assays were performed in the above assays. *** miR-377 / miR-494 in this article represents miR-377-3p / miR-494-3p , respectively

    Article Snippet: The following antibodies were used in this study: anti-AKT (CST, #9272), anti-phosphorylated-AKT (Ser-473) (CST, #9271), anti-IGF1R (Proteintech, #20,254-1-AP), anti-phosphorylated-S6 Ribosomal Protein (Ser235/236) (CST, #4858), anti-S6 Ribosomal Protein (5G10) (CST, #2217), anti-PARP (CST, #9542), anti-p21 (Proteintech, 10,355-1-AP), anti-β-actin (TransGen, HC201).

    Techniques: Western Blot, Expressing, Luciferase, Cotransfection, Over Expression, Plasmid Preparation, Immunohistochemistry, Two Tailed Test

    circVAPA facilitates SCLC cell viability via the miR-377-3p & miR-494-3p /IGF1R/AKT axis. a Two databases (miRwalk and ENCORI) were used to predict the potential target mRNAs of miR-377-3p and miR-494-3p . The Venn diagram shows the number of overlapping miRNAs. b and c Dual-luciferase reporter assay was performed to validate the interaction of IGF1R and miR-377-3p ( b ) or miR-494-3p ( c ). 293T cells were co-transfected with a dual-luciferase reporter vector containing the putative binding sites/ mutated sequences for IGF1R and miR-377-3p / miR-494-3p , miR-377-3p / miR-494-3p mimics or negative control mimics (mimic-NC), respectively. Lu- IGF1R -DM represents Lu- IGF1R -Mut 1 & 2, which contains two mutation sites. d-e RT-qPCR analysis of miR-377-3p / miR-494-3p ( d ) and IGF1R ( e ) in 3-paired SCLC and paraSCLC samples. 18S rRNA was used as the internal control. f-j RT-qPCR analysis of IGF1R expression in SCLC cells transiently transfected with siRNAs or plasmids as indicated. k and l Cell viability ( k ) and colony formation ( l ) assays of SCLC cells transiently transfected with siRNAs, plasmids, miRNA inhibitors or mimics as indicated. SCR, siRNA with scrambled sequences; si- circVAPA , the co-transfection of two independent siRNAs target circVAPA ; EV, the empty vector; circVAPA , the circVAPA overexpression plasmid; miR-377 mimic / miR-494 mimic , transiently overexpressing miR-377-3p / miR-494-3p , respectively; miR-377 inhibitor / miR-494 inhibitor , transiently suppressing miR-377-3p / miR-494-3p , respectively; si- IGF1R , an independent siRNA targeting IGF1R . (All data are presented as the mean ± SD; ns, no significance; * P < 0.05; ** P < 0.01; *** P < 0.001 by two-tailed Student’s t-test). Three independent assays were performed in the above assays. *** miR-377 / miR-494 represents miR-377-3p / miR-494-3p , respectively

    Journal: Molecular Cancer

    Article Title: CircVAPA promotes small cell lung cancer progression by modulating the miR-377-3p and miR-494-3p /IGF1R/AKT axis

    doi: 10.1186/s12943-022-01595-9

    Figure Lengend Snippet: circVAPA facilitates SCLC cell viability via the miR-377-3p & miR-494-3p /IGF1R/AKT axis. a Two databases (miRwalk and ENCORI) were used to predict the potential target mRNAs of miR-377-3p and miR-494-3p . The Venn diagram shows the number of overlapping miRNAs. b and c Dual-luciferase reporter assay was performed to validate the interaction of IGF1R and miR-377-3p ( b ) or miR-494-3p ( c ). 293T cells were co-transfected with a dual-luciferase reporter vector containing the putative binding sites/ mutated sequences for IGF1R and miR-377-3p / miR-494-3p , miR-377-3p / miR-494-3p mimics or negative control mimics (mimic-NC), respectively. Lu- IGF1R -DM represents Lu- IGF1R -Mut 1 & 2, which contains two mutation sites. d-e RT-qPCR analysis of miR-377-3p / miR-494-3p ( d ) and IGF1R ( e ) in 3-paired SCLC and paraSCLC samples. 18S rRNA was used as the internal control. f-j RT-qPCR analysis of IGF1R expression in SCLC cells transiently transfected with siRNAs or plasmids as indicated. k and l Cell viability ( k ) and colony formation ( l ) assays of SCLC cells transiently transfected with siRNAs, plasmids, miRNA inhibitors or mimics as indicated. SCR, siRNA with scrambled sequences; si- circVAPA , the co-transfection of two independent siRNAs target circVAPA ; EV, the empty vector; circVAPA , the circVAPA overexpression plasmid; miR-377 mimic / miR-494 mimic , transiently overexpressing miR-377-3p / miR-494-3p , respectively; miR-377 inhibitor / miR-494 inhibitor , transiently suppressing miR-377-3p / miR-494-3p , respectively; si- IGF1R , an independent siRNA targeting IGF1R . (All data are presented as the mean ± SD; ns, no significance; * P < 0.05; ** P < 0.01; *** P < 0.001 by two-tailed Student’s t-test). Three independent assays were performed in the above assays. *** miR-377 / miR-494 represents miR-377-3p / miR-494-3p , respectively

    Article Snippet: The following antibodies were used in this study: anti-AKT (CST, #9272), anti-phosphorylated-AKT (Ser-473) (CST, #9271), anti-IGF1R (Proteintech, #20,254-1-AP), anti-phosphorylated-S6 Ribosomal Protein (Ser235/236) (CST, #4858), anti-S6 Ribosomal Protein (5G10) (CST, #2217), anti-PARP (CST, #9542), anti-p21 (Proteintech, 10,355-1-AP), anti-β-actin (TransGen, HC201).

    Techniques: Luciferase, Reporter Assay, Transfection, Plasmid Preparation, Binding Assay, Negative Control, Mutagenesis, Quantitative RT-PCR, Expressing, Cotransfection, Over Expression, Two Tailed Test

    CircVAPA facilitates SCLC proliferation through regulating IGF1R in vivo and in vitro. a Western blot analysis of the effect of SCLC stable cell line with circVAPA knockdown or the control with or without IGF1R inhibitor (drug BMS-536924) on AKT and its downstream protein expression. b-c Cell viability ( b ) and colony formation ( c ) assays of the SCLC stable cell line with circVAPA knockdown or the control with or without IGF1R inhibitor (drug BMS-536924). d-f Therapeutic efficacy of circVAPA depletion and IGF1R inhibitor (drug BMS-536924) as single-agents or in combination in vivo ( n = 5 for each group). Tumor weights ( d ), tumor volume curves ( e ), and tumor photos ( f ) of xenograft tumors treated with circVAPA depletion and IGF1R inhibitor alone or in combination. g Immunohistochemistry analysis of IGF1R and p-AKT in tumors. Scale bar, 50 μm. h Model patterns of circVAPA / miR-377-3p & miR-494-3p /IGF1R/AKT axis. Vehicle, negative control cells for silencing circVAPA ; sh- circVAPA , stable cell line with lentivirus shRNA to knockdown circVAPA ; IGF1Ri, the addition of IGF1R inhibitor (drug BMS-536924). (All data are presented as the mean ± SD; ns, no significance; * P < 0.05; ** P < 0.01; *** P < 0.001 by two-tailed Student’s t-test). Three independent assays were performed in the above assays

    Journal: Molecular Cancer

    Article Title: CircVAPA promotes small cell lung cancer progression by modulating the miR-377-3p and miR-494-3p /IGF1R/AKT axis

    doi: 10.1186/s12943-022-01595-9

    Figure Lengend Snippet: CircVAPA facilitates SCLC proliferation through regulating IGF1R in vivo and in vitro. a Western blot analysis of the effect of SCLC stable cell line with circVAPA knockdown or the control with or without IGF1R inhibitor (drug BMS-536924) on AKT and its downstream protein expression. b-c Cell viability ( b ) and colony formation ( c ) assays of the SCLC stable cell line with circVAPA knockdown or the control with or without IGF1R inhibitor (drug BMS-536924). d-f Therapeutic efficacy of circVAPA depletion and IGF1R inhibitor (drug BMS-536924) as single-agents or in combination in vivo ( n = 5 for each group). Tumor weights ( d ), tumor volume curves ( e ), and tumor photos ( f ) of xenograft tumors treated with circVAPA depletion and IGF1R inhibitor alone or in combination. g Immunohistochemistry analysis of IGF1R and p-AKT in tumors. Scale bar, 50 μm. h Model patterns of circVAPA / miR-377-3p & miR-494-3p /IGF1R/AKT axis. Vehicle, negative control cells for silencing circVAPA ; sh- circVAPA , stable cell line with lentivirus shRNA to knockdown circVAPA ; IGF1Ri, the addition of IGF1R inhibitor (drug BMS-536924). (All data are presented as the mean ± SD; ns, no significance; * P < 0.05; ** P < 0.01; *** P < 0.001 by two-tailed Student’s t-test). Three independent assays were performed in the above assays

    Article Snippet: The following antibodies were used in this study: anti-AKT (CST, #9272), anti-phosphorylated-AKT (Ser-473) (CST, #9271), anti-IGF1R (Proteintech, #20,254-1-AP), anti-phosphorylated-S6 Ribosomal Protein (Ser235/236) (CST, #4858), anti-S6 Ribosomal Protein (5G10) (CST, #2217), anti-PARP (CST, #9542), anti-p21 (Proteintech, 10,355-1-AP), anti-β-actin (TransGen, HC201).

    Techniques: In Vivo, In Vitro, Western Blot, Stable Transfection, Expressing, Immunohistochemistry, Negative Control, shRNA, Two Tailed Test